NCT04797143 Impact of a Multidisciplinary Consultation Program on Drug Adherence in First Oral Anticancer Treatment
| NCT ID | NCT04797143 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Multidisciplinary Consultation Program |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2021-03-11 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2021-03-11 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Oncology management has changed dramatically over the last decade with the approval and rapid adoption of newly targeted oral oncology medications. The movement to oral oncology medications has altered the balance of risks and adverse effects (AEs) in the treatment of cancer care. These treatments are associated with a different constellation of AEs and drug interactions. Patients receiving treatment with oral anticancer treatment (OAT) encounter several barriers to adherence, which may include limited access to specialty medications, severe adverse effects, complex medication regimens, and special handling precautions. Medication nonadherence not only reduces the efficacy of drug therapy but also has the potential to increase healthcare expenditures due to disease-related hospitalizations. The purpose of this study is to evaluate the drug adherence in cancer patients, using the medication possession ratio (MPR), before and after the implementation of a multidisciplinary consultation program (MCP), on initiation of OAT.
Eligibility Criteria
Inclusion Criteria: * French speaking patients with a newly diagnosed or relapsed cancer, regardless of location and introduction of oral anticancer treatment Exclusion Criteria: * patients treated with hormone therapy only * Patient with severe psychiatric disorders * patient who does not speak the French language
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04797143 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multidisciplinary Consultation Program. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04797143 currently recruiting?
Yes, NCT04797143 is actively recruiting participants. Contact the research team at terrier-lenglet.aurelie@chu-amiens.fr for enrollment information.
Where is the NCT04797143 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT04797143 clinical trial?
NCT04797143 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 300 participants.